Clinical data and extent of methylation for 16 patients with acute myeloid leukemia (sorted by number of methylation events)
| FAB . | Age (y) . | Sex . | Cytogenetics . | Duration of CR (mo) . | Survival (mo) . | Tissue studied for RLGS . | No. methylation events per 1740 RLGS fragments . | % of RLGS profile methylated . |
|---|---|---|---|---|---|---|---|---|
| M4 | 32 | M | 46,XY,t(9;11)(p22;q23) | 8.3 | 12.1 | PB | 0 | 0 |
| M5A | 32 | M | 46,XY | 7.1* | 8.7 | PB | 2 | 0.1 |
| unclassified | 57 | M | 61,XY,+X,+1,+5,+8,+9,+10,+11, +12,+13,del(17)(p11),−18,+19, +20,+21,+21,+22,+22,+MAR1 | 1.4* | 2.7 | PB | 2 | 0.1 |
| M1 | 58 | F | 46,XX | 18.6+ | 21.8+ | PB | 7 | 0.4 |
| M2† | 61 | M | 46,XY | 20.5 | 30.5 | PB | 11 | 0.6 |
| M1† | 33 | M | 46,XY | 33.9+ | 34.8+ | PB | 20 | 1.1 |
| M5B | 36 | M | 43,XY,add(1)(p36.3),7del(2)(p21p23), −2,del(10)(p11.2p173),del(12)(p11.2p13),−13,−15 | 19.6 | 21.1 | PB | 20 | 1.1 |
| M5B† | 43 | M | 46,XY | 22.9+ | 23.7+ | BM | 23 | 1.3 |
| unclassified† | 30 | M | 46,XY | 29.4+ | 30.5+ | PB | 26 | 1.5 |
| M1† | 45 | F | no mitoses | 29.6+ | 30.7+ | PB | 29 | 1.7 |
| M2† | 31 | M | 47,XY,+10/47,XY,del(9)(q13q22),+10 | 9.9 | 26.0+ | PB | 30 | 1.7 |
| M4† | 54 | F | 46,XX | 34.2+ | 35.1+ | BM | 36 | 2.1 |
| M2† | 36 | M | 46,XY | 7.4 | 22.3+ | BM | 36 | 2.1 |
| M5B† | 22 | M | 47,XY,+8 | 3.9 | 8 | PB | 56 | 3.2 |
| M0† | 32 | M | 49,XY,+4,+7,+9,t(9;11)(q34;q13) | 3.2 | 25.0+ | PB | 81 | 4.7 |
| M1† | 47 | M | no mitoses | 16.1+ | 16.9+ | PB | 145 | 8.3 |
| FAB . | Age (y) . | Sex . | Cytogenetics . | Duration of CR (mo) . | Survival (mo) . | Tissue studied for RLGS . | No. methylation events per 1740 RLGS fragments . | % of RLGS profile methylated . |
|---|---|---|---|---|---|---|---|---|
| M4 | 32 | M | 46,XY,t(9;11)(p22;q23) | 8.3 | 12.1 | PB | 0 | 0 |
| M5A | 32 | M | 46,XY | 7.1* | 8.7 | PB | 2 | 0.1 |
| unclassified | 57 | M | 61,XY,+X,+1,+5,+8,+9,+10,+11, +12,+13,del(17)(p11),−18,+19, +20,+21,+21,+22,+22,+MAR1 | 1.4* | 2.7 | PB | 2 | 0.1 |
| M1 | 58 | F | 46,XX | 18.6+ | 21.8+ | PB | 7 | 0.4 |
| M2† | 61 | M | 46,XY | 20.5 | 30.5 | PB | 11 | 0.6 |
| M1† | 33 | M | 46,XY | 33.9+ | 34.8+ | PB | 20 | 1.1 |
| M5B | 36 | M | 43,XY,add(1)(p36.3),7del(2)(p21p23), −2,del(10)(p11.2p173),del(12)(p11.2p13),−13,−15 | 19.6 | 21.1 | PB | 20 | 1.1 |
| M5B† | 43 | M | 46,XY | 22.9+ | 23.7+ | BM | 23 | 1.3 |
| unclassified† | 30 | M | 46,XY | 29.4+ | 30.5+ | PB | 26 | 1.5 |
| M1† | 45 | F | no mitoses | 29.6+ | 30.7+ | PB | 29 | 1.7 |
| M2† | 31 | M | 47,XY,+10/47,XY,del(9)(q13q22),+10 | 9.9 | 26.0+ | PB | 30 | 1.7 |
| M4† | 54 | F | 46,XX | 34.2+ | 35.1+ | BM | 36 | 2.1 |
| M2† | 36 | M | 46,XY | 7.4 | 22.3+ | BM | 36 | 2.1 |
| M5B† | 22 | M | 47,XY,+8 | 3.9 | 8 | PB | 56 | 3.2 |
| M0† | 32 | M | 49,XY,+4,+7,+9,t(9;11)(q34;q13) | 3.2 | 25.0+ | PB | 81 | 4.7 |
| M1† | 47 | M | no mitoses | 16.1+ | 16.9+ | PB | 145 | 8.3 |
“+” indicates that remission and/or survival status is ongoing at time of last follow-up.
FAB indicates French-American-British classification system; CR, complete remission; RLGS, restriction landmark genomic scanning; PB, peripheral blood; BM, bone marrow.
Patient died of treatment-related complications without evidence of leukemia.
Patient has at least one methylation event on chromosome 11.